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Abstract (word count 250)
Background & Aims: HVPG decrease ≥20% or ≤12mmHg (“responders”) indicates good 
prognosis during propranolol/nadolol treatment but requires two HVPG measurements. We aimed 
at simplifying risk-stratification after variceal bleeding using clinical data and HVPG. Methods: 
193 cirrhotic patients (62% with ascites and/or hepatic encephalopathy, HE) included within 7-
days of bleeding had HVPG measured before and at 1-3 months of treatment with 









This article is protected by copyright. All rights reserved
rebleeding/transplantation-free survival for 4-years. Another cohort (n=231) served as validation 
set.  
Results: During follow-up 45 patients had variceal bleeding and 61 died. HVPG-responders 
(n=71) had lower rebleeding-risk (10% vs 34%, p=0.001) and better survival than 122 non-
responders (61% vs 39%, p=0.001). Patients with/HE (n=120) had lower survival than patients 
without (40% vs 63%, p=0.005). Among patients with ascites/HE, those with baseline 
HVPG≤16mmHg (n=16) had low rebleeding-risk (13%). By contrast, among patients with 
ascites/HE and baseline HVPG>16mmHg, only HVPG-responders (n=32) had good prognosis, 
with lower rebleeding-risk and better survival than non-responders (n=72) (respective proportions: 
7% vs 39%,p=0.018; 56% vs 30% p=0.010). These findings allowed developing a new algorithm 
for risk-stratification in which HVPG-response was only measured in patients with ascites and/or 
HE and baseline HVPG>16mmHg. This algorithm reduced the grey-zone (high-risk patients not 
dying on follow-up) from 46% to 35% and decreased by 42% the HVPG measurements required. 
The validation cohort confirmed these results.    
Conclusion: Restricting HVPG measurements to patients with ascites/HE and measuring HVPG-
response only if baseline HVPG>16mmHg improves detection of high-risk patients while 
markedly reducing the number of HVPG measurements required.  
Keywords: Portal hypertension; bleeding; Survival; Cirrhosis 
Abbreviations: EBL: endoscopic band ligation; FHVP: Free Hepatic Venous Pressure; HE: 
hepatic encephalopathy; HVPG: Hepatic Venous Pressure Gradient; NSBBs: non-selective beta-
adrenergic blockers; WHVP: Wedged Hepatic Venous Pressure; OLT: orthotopic liver 
transplantation; TIPS: transjugular intrahepatic porto-systemic shunt.
Grant Support: supported by Grants from the Instituto de Salud Carlos III, Ministerio de 
Economia y Competitividad (PI 13/341, PI10/1552,PI10/01552, PI13/02535 and PI16/01992). The 
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INTRODUCTION
Variceal bleeding is a major complication of cirrhosis, with a high risk of rebleeding 
and high mortality in untreated patients. This makes mandatory to implement 
effective therapy, which nowadays consists in the combination of non-selective 
beta-blockers (NSBBs) and repeat endoscopic band ligation sessions (1,2). The 
hepatic venous pressure gradient (HVPG) provides valuable prognostic information 
in patients with cirrhosis during the prevention of recurrent variceal bleeding (3,4). 
Many studies (5-8) and meta-analysis (9,10) have consistently shown that a HVPG 
reduction ≥20% of baseline or to values ≤12mmHg during long-term treatment is 
associated with a reduced risk of recurrent variceal bleeding, of other portal 
hypertension related complications, and improved survival. 
However, the high specificity of the hemodynamic response indicating a good 
prognosis is not associated with a high sensitivity, since up to 48% of patients who 
are HVPG non-responders to NSBBs will not rebleed during the follow-up, 
representing what has been named as a “grey zone” (11). Such relatively low 
sensitivity hampers risk stratification and diminishes the cost-effectiveness of 
HVPG-guided therapy.
Baseline HVPG in cirrhosis bears prognostic significance (3,4,7,8,12-22). A 
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developing varices, decompensation, hepatocellular carcinoma and decompensation 
after liver resection for hepatocellular carcinoma. Furthermore, several studies have 
shown that a baseline HVPG over 16 mmHg identifies patients with reduced 
survival (23-26). 
On the other hand, it has recently been emphasized that prognosis of cirrhosis is 
markedly dependent on the stage of the disease. Prognosis is good while patients are 
compensated, and worsens dramatically upon clinical decompensation – defined by 
the development of ascites, variceal bleeding or hepatic encephalopathy (HE) (27). 
Within the decompensated stage, prognosis is in turn different if the decompensation 
is due to variceal bleeding alone or if this occurs in the form of, or associated with 
ascites and/or HE, in which case prognosis is much worse. Patients with ascites 
and/or HE on top of bleeding have a high mortality risk, which has led to 
recommend that the main goal of therapy in such cases should be survival (2,28-29). 
Current recommended therapy for the prevention of variceal rebleeding is the 
combination of NSBBs plus endoscopic band ligation (EBL) (2), both for patients 
with or without ascites/HE. This study explores in a large series of patients receiving 
recommended treatment for the prevention of variceal rebleeding whether 
considering the presence/absence of ascites and/or HE and adding the finding of a 
baseline HVPG below or over 16mmHg to the traditional criteria of hemodynamic 




The study cohort comprises n=193 patients with cirrhosis receiving NSBBs and 
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and at the Gastroenterology Division, Hospital de Sant Pau, Barcelona in whom 
HVPG response to NSBBs (after 1-3 months on NSBBs) was evaluated and who 
were included in previously published studies (29-33). The study is a nested 
retrospective analysis using the initial database. Inclusion criteria for the present 
study were: diagnosis of cirrhosis (based on liver biopsy and/or unequivocal clinical 
data and compatible findings on imaging techniques); admission for variceal 
bleeding within the previous 7 days; baseline HVPG values of at least 12 mmHg; 
subsequent long-term treatment with NSBBs (propranolol or nadolol) combined 
with repeated EBL sessions; and a second HVPG measurement after 1 to 3 months 
of continued pharmacological therapy. Patients with hepatocellular carcinoma at 
baseline, portal vein thrombosis, contraindications to beta-blockers, previous TIPS 
or surgical shunts or cholestatic liver disease were excluded. Two-hundred and 
thirty-one patients who received NSBBs without concomitant EBL included in 
previous studies from the same institutions (30, 35-36) and who had baseline and 
repeat HVPG measurements served as a validation cohort of the proposed algorithm 
for risk-stratification. Both in the training and validation cohorts, patients were 
considered positive for ascites if they presented clinical evidence of ascites at 
inclusion or if they had clinically evident ascites confirmed by paracentesis in the 
previous 12-months. HE was considered to be present when clinically evident (grade 
≥ 2 in the West Haven scale) and diagnosed by a physician during hospital 
admission or at an outpatient visit. All included patients have given their informed 
consent to the initial studies. The retrospective collection of clinical and 
hemodynamic data for the current study was approved by the ethical committee for 
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Baseline hemodynamic studies were performed before starting NSBBs for 
preventing variceal rebleeding. The study was performed once the patients were in 
stable conditions, at days 4-7 after admission for variceal bleeding. In brief, under 
local anaesthesia, a venous introducer was placed in the right internal jugular vein 
by the Seldinger technique. Under fluoroscopy, a 7F balloon-tipped catheter was 
advanced into the main right hepatic vein for measuring wedged hepatic venous 
pressure (WHVP) and free hepatic venous pressure (FHVP) as previously described 
(4). WHVP was measured after verifying adequate occlusion of the hepatic vein by 
the inflated balloon, while FHVP was measured at 2-3 cm of the outlet of the 
hepatic vein into the inferior vena cava. All measurements were taken in triplicate. 
Permanent tracings were obtained in a multichannel recorder (Mac-Lab®, GE 
Healthcare, Freiburg, Germany, for Hospital Clinic; PowerLab 8SP, AD 
Instruments, for Hospital Sant Pau), and were reviewed specifically for this study by 
experienced investigators (VLM, JGA, JCGP, JB, CV) unaware of the clinical data 
of the patients. 
HVPG was calculated as the mean of triplicate measurements of WHVP and FHVP. 
The second hemodynamic study to evaluate the hemodynamic response to NSBBs 
was performed 1 to 3 months later, once the patient had reached a stable dose of the 
NSBB for at least two weeks. 
Titration of NSBBs and Follow-Up
After the hemodynamic evaluation, all patients were started on oral propranolol (20 
mg b.i.d.) or nadolol (20 to 80 mg o.i.d), that were increased stepwise, if clinically 
tolerated, until heart rate had fallen to 50-55/minute, while systolic blood pressure 











This article is protected by copyright. All rights reserved
The first EBL session was performed at admission for the control of acute variceal 
bleeding. Sessions were repeated every 3-4 weeks until variceal eradication (29). 
Follow-up endoscopies were scheduled at 3 months, 6 months and every 12 months 
thereafter. In case of variceal recurrence, additional EBL sessions were performed. 
All patients were followed-up in the outpatient clinic at 1, 3, and 6 months, and 
every 3-6 months thereafter. Medical history, physical examination, biochemistry, 
hematologic tests and abdominal ultrasound were performed every six-months. 
Follow-up data were collected for up to 4 years (follow-up was extended for those 
patients censored at two-year in the original studies), or until death or liver 
transplantation (OLT). Patients who stopped NSBBs were censored the day of drug 
withdrawal (per treatment received analysis). Clinical events assessed were 
rebleeding, death or liver transplantation defined according to Baveno criteria (2). 
Patients who discontinued propranolol/nadolol were censored at the time of 
treatment discontinuation; the same was done for patients who received TIPS during 
the follow-up. 
Statistical Analysis            
Statistical analysis was performed with SPSS 19.0 package (SPSS, Chicago, IL) and 
R (http://www.r-project.org). Data are reported as frequencies or means with 
standard deviation. Comparisons for continuous and categorical data were 
performed with unpaired Student t test, Mann–Whitney test, or Fisher exact test as 
appropriate. For the survival analysis, we considered two clinical end-points: 
rebleeding and rebleeding/OLT-free survival. Rebleeding risk was tested as 
cumulative incidence function which takes into account death or liver 
transplantation as competing risks (37). Rebleeding and OLT-free survival on 
follow-up are depicted using Kaplan-Meier curves. The log-rank test was used to 
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association with rebleeding and survival were adjusted by introducing independent 
variables in the Fine Gray model for competing risk analysis (38) and the 
multivariable Cox proportional hazards model, respectively. Redundant variables 
were not introduced in the final analysis. The contribution of each variable was 
estimated by the HR with its 95% confidence intervals (CIs). Comparison of the 
number of patients misclassified as belonging to a high-risk category by traditional 
criteria and by the new criteria derived from the study was done with the McNemar 
test. Algorithms for risk stratification based on baseline HVPG, presence/absence of 
ascites/HE and HVPG response were constructed. Significance was established at 
p<0.05.
RESULTS
Clinical and hemodynamic characteristics of patients included in the study.
One-hundred-ninety-three patients were included in the study cohort. Clinical 
characteristics and hemodynamic data of the patients are reported in Table 1. 
Seventy-one (37%) exhibited a fall in HVPG below 12 mmHg or of at least 20% of 
the baseline value and were considered “HVPG-responders” to continued 
administration of NSBB, 122 (63%) were non-responders. As per current 
recommendations, both responders and non-responders were kept on NSBBs 
treatment and continued EBL. For 73 patients (38%) bleeding alone was the index 
manifestation of clinical decompensation, while for 120 patients (62%) bleeding 
occurred as a further decompensation on top of ascites (n=74; 38%), of HE (n=5; 
3%), or of ascites plus HE (n=41; 21%). As patients with HE alone (on top of 
bleeding) were only 5, these were added to the other 74 patients with ascites alone to 
make up a group of 79 patients with bleeding+ascites/HE (41%). A comparison of 
the clinical characteristics and hemodynamics in these different stages of 
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bleeding had better liver function, lower portal pressure and were more frequently 
HVPG-responders to continued administration of NSBB than the other groups.
Prognosis according to HVPG response
During follow-up (median 31 months), 45 patients experienced variceal rebleeding, 
61 patients died and 10 were transplanted according with the local transplantation 
policy based on MELD score and at least 6-month of verified abstinence from 
alcohol. Rebleeding occurred in 39/122 non-responders vs 6/71 HVPG responders 
(cumulative 4-year rebleeding risk: 34% vs 10%; HR: 4.332, 95%-CI: 1.854-10.075; 
p=0.001) (Fig. 1). According to HVPG response, 83/122 (68%) non-responders 
(representing 43% of the cohort) were misclassified as high-risk since they did not 
rebleed on follow-up (“grey zone”). The cumulative 4-year OLT-free survival was 
61% in responders vs 39% in non-responders (HR 2.142, 95%-CI: 1.321-3.474; 
p=0.002).
Prognosis according to presence of ascites/HE and to baseline HVPG >16 mmHg
As expected, presence of other manifestations of clinical decompensation at the 
moment of bleeding (ascites and/or HE; n=120) markedly influenced 4-year survival 
(40% vs 63%, p=0.005). The rebleeding-risk increased and survival progressively 
worsened with increasing number of manifestations of decompensation (e.g. patients 
with bleeding as the only decompensation event Vs patients with bleeding + 
ascites/HE Vs patients with bleeding + ascites + HE). Specifically, in the 79 patients 
presenting with bleeding + ascites/HE, 4-year rebleeding was 21% and survival 
48%, which were better than those observed in the 41 patients presenting with 
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As for baseline HVPG, 34 patients (18%) had a pre-treatment HVPG ≤16 mmHg. 
This was associated with a low rebleeding risk even in patients with poor prognostic 
indicators. Indeed, rebleeding was low and similar in the 16 patients with baseline 
HVPG ≤16mmHg presenting with bleeding + ascites and/or HE as in the 19 patients 
HVPG non-responders with baseline HVPG ≤16mmHg (13% and 12% 
respectively).   Corresponding figures for survival were also similar: 47% and 52%. 
By the contrary, in patients with a combination of negative prognostic markers, such 
as patients presenting with bleeding plus ascites and/or HE who had a baseline 
HVPG >16 mmHg, the HVPG response to NSBBs strongly correlated with the 
outcomes. In this subgroup, non-responders (n=72) had a 39% rebleeding risk, much 
higher than the 7% observed in hemodynamic responders (n=32) and the 13% of 
rebleeding-risk already shown in patients presenting with bleeding plus ascites 
and/or HE who had baseline HVPG ≤16mmHg (n=16) (p=0.018) (Supplementary 
Figure 1, panel A). Survival was also worse in patients presenting with bleeding 
plus ascites and/or HE together with a baseline HVPG >16mmHg and who were 
non-responders to NSBBs (30%), as compared with patients in the same category 
who were either HVPG responders (56%) or who had a baseline HVPG ≤16mmHg 
(47%) (p=0.010) (Supplementary Figure 1, panel B).
Refining risk-stratification in cirrhosis: a new clinical and hemodynamic 
algorithm
The above data allow establishing a novel algorithm for risk stratification in patients 
with cirrhosis surviving an episode of variceal bleeding. Given the high survival 
(63%) of patients with only variceal bleeding, the algorithm takes into account, 
firstly, the presence of ascites and/or HE in addition to bleeding and, secondly, the 
baseline HVPG. The new algorithm restricts measurement of the baseline HVPG to 
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assessment of the hemodynamic response to those with ascites and/or HE who have 
a baseline HVPG >16 mmHg (Figure 2, panel A). Using this algorithm, rebleeding 
occurred in 27/72 of patients classified as “high-risk” (i.e. those with ascites and/or 
HE, baseline HVPG >16mmHg and absence of hemodynamic response) Vs 18/121 
of the “low-risk patients” (cumulative 4-year rebleeding risk: 39% vs 17%; HR: 
2.882, 95%-CI: 1.609-5.164; p<0.001) (Figure 2, panel B). 
It is worth noting that a sensitivity analysis demonstrated that a range of baseline 
HVPG from 15 mmHg to 17 mmHg performed similarly, but 16 mmHg was the best 
cut-off to use as an additional prognostic criterion on top of ascites/HE. This 
indicates that our finding is robust, as the variability of HVPG measurements is 
below 1 mmHg (39). We also performed an exploratory analysis comparing patients 
with and without active alcohol consumption (patients with active alcohol intake: 
n=58 in low-risk, n=37 in high-risk; patients without active alcohol consumption: 
n=63 in low-risk, n=34 in high-risk) and the discriminative ability of the algorithm 
for survival did not change (data not shown).
The new algorithm decreased the number of patients incorrectly classified as ‘high-
risk’ for rebleeding: the number and relative proportion of patients who did not 
rebleed on follow up among the group classified as high-risk for the old and new 
algorithm were, respectively, 83/122 (68%) (corresponding to 43% of the total 
cohort) and 45/72 (62%) (corresponding to 23% of the total cohort; p<0.001, 
McNemar test), while the number of patients who rebled among the low-risk group 
were 6/71 (8.4%) for the old-algorithm and 18/121 (14.8%) for the new algorithm 
(corresponding respectively to 3% and 9% of the total cohort). This suggests the 
new algorithm performs better among high-risk patients. Similar findings were 
observed for survival. Indeed, the number of patients misclassified as high-risk, 
respectively for the old and the new algorithm, for this end-point was 56/122(46%) 
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McNemar test). The corresponding numbers of misclassified low-risk patients with 
regards to mortality were 22/71 (31%) using the initial algorithm and of 41/122 
(33%) when using the new algorithm.
Moreover, the new algorithm allowed markedly decreasing the number of 
hemodynamic measurements needed for risk-stratification. Thus, 73 patients without 
ascites/HE would not need any measurement, 16 patients with ascites and/or HE and 
a baseline HVPG ≤16 mmHg would need only one measurement, and 104 with 
ascites and/or HE and a baseline HVPG >16 mmHg would need two measurements, 
for a total of 224 HVPG measurements vs 386 using the traditional HVPG response-
based risk-assessment, thus saving 42% of HVPG measurements (Figure 3).
The new algorithm had an excellent prognostic value for survival free of rebleeding 
or OLT. This was analogous to that obtained by measuring the HVPG-response 
(Fig. 2, panel C), but saving 42% of the HVPG examinations.
Variables that in univariate analysis were found to be significantly associated with 
being a high-risk patient (Supplementary Table 1) and with rebleeding and survival 
on follow-up (Supplementary Table 2) were introduced in a multivariate analysis 
(Table 2). Belonging to the high-risk group was the only independent predictor of 
rebleeding (HR: 2.739, 95%-CI: 1.436-5.226; p=0.002) and the strongest predictor 
of survival free of rebleeding/OLT (HR: 2.539, 95%-CI: 1.546-4.169; p<0.001), 
followed by low serum sodium levels (HR: 0.943, 95%-CI: 0.899-0.990; p=0.018) 
and with a residual trend for MELD score (HR:1.042, 95%-CI: 0.993-1.095; 
p=0.097).
Validation set
Supplementary Table 3 reports the clinical characteristic of the 231 patients 
included in the validation set. Over the 4-year follow-up, 65 patients experienced 
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As depicted in Figure 4, the prognostic performance of the new algorithm was 
successfully validated both for risk of rebleeding (Figure 4, panel A) and survival 
(Figure 4, panel B).
DISCUSSION
In this study we present a new algorithm simplifying and improving risk 
stratification in patients with cirrhosis who receive recommended treatment with 
NSBBs and EBL to prevent recurrent variceal bleeding. This new strategy, derived 
from a thorough analysis of two large series of patients (training and validation 
sets), is based on incorporating data on the stage of decompensation of cirrhosis and 
results of baseline HVPG measurements. In this new algorithm, HVPG 
measurements are performed at time of the index bleed only in patients with ascites 
and/or HE, and assessment of the HVPG response to NSBBs is only done if baseline 
HVPG is over 16 mmHg. Therefore, it defines as ‘low-risk’ those patients with 
variceal bleeding who have no ascites/HE, as well as patients with ascites and/or HE 
but with baseline HVPG ≤16 mmHg. By contrast, the algorithm considers as ‘high-
risk’ those patients with variceal bleeding who also have all of the following: a) 
ascites and/or HE, b) HVPG >16 mmHg before starting NSBBs, and c) lack of an 
adequate hemodynamic response to continued NSBB (failure to decrease HVPG by 
at least 20% of baseline or ≤12 mmHg).
This new strategy is superior to the traditional in several relevant aspects. First, it 
would have obviated any hemodynamic measurements in 38% of our patients -those 
without ascites or HE at time of the index variceal bleeding- and would have 
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100% in the traditional strategy). This represents reducing by almost half the 
number of hepatic vein catheterisation studies to be performed, thus halving the 
economic cost, health care burden and patient discomfort required in the previous 
strategy of risk-stratification. Second, the new strategy is associated with an 
improved accuracy of the prediction of patients at “high-risk” of rebleeding or death 
during a four-year follow-up. With regards to rebleeding, the number of patients 
classified as “high-risk” but who do not bleed during the follow-up (the so called 
“grey zone”) decreased from 83 with the traditional strategy to 45 with the new 
algorithm (from 43% to 23% of the total cohort). Thirdly, the new algorithm also 
predicted survival-free of OLT and of rebleeding, an end-point which is more 
important than rebleeding alone in patients with advanced liver failure, particularly 
when bleeding occurs in patients with ascites and/or HE, a subgroup in which death 
is frequent and the most relevant event (2, 28-29). 
For all these reasons, it is possible that this new strategy for risk-stratification, with 
much better cost-effectiveness than the traditional one, might lead to changes in the 
approach to treatment. This is particularly likely considering that HVPG-guided 
therapy improved the outcome of therapy in a recent trial (40).  High-risk patients 
are usually referred to be considered for TIPS or liver transplantation to tertiary care 
centres. It is likely that in these circumstances it would be easier to implement a 
therapeutic protocol including stratification based on clinical data and HVPG. The 
practical implication of applying this new algorithm can only be addressed by an 
adequately designed study. However, the new algorithm has the potential for 
selecting better the group of high-risk patients, by markedly reducing its number and 
by having lower “grey-zones” for rebleeding and death (patients included in the high 
risk group category but who do not bleed or dye on follow-up) (11). It is possible 
that this high risk patients could benefit from a more aggressive therapeutic 
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bleeding (41) and for “difficult ascites” (42), advancing a decision for TIPS (instead 
of using it as rescue therapy after failure of standard treatment) may be life-saving. 
Therefore, it may be worth trying this approach in the high-risk population defined 
by the new algorithm (patients with ascites, HVPG > 16 mmHg, and non-responders 
to propranolol).
Importantly, the concept that patients with several decompensating events (e.g. 
bleeding + ascites and/or HE) have the worst prognosis is in line with the recent 
survival models proposed for the natural history of cirrhosis (27,29). The prognostic 
information provided by the cut off of 16 mmHg is not entirely new as 5 previous 
studies showed it to be a predictor of survival (8,23-26). However, none of these 
studies investigated its prognostic value in the context of the medical treatment of 
portal hypertension. 
Our study has strengths and limitations. A major strength is that it is based in large 
cohorts of patients, both for the training and the validation cohort, mostly included 
in prospective clinical trials in two expert centres, so the results are robust. Among 
the limitations it should be noted that the subgroup of patients with only HE on top 
of variceal bleeding was quite small (n=5) so its role aggravating the prognosis of 
patients with bleeding and ascites could not be fully characterized; that’s why these 
were pooled with patients with ascites on top of bleeding. Secondly, from this study 
we cannot extrapolate if the prognostic value of the new algorithm would extend to 
patients treated prophylactically, before the first bleeding or clinical decompensation 
that have a much lower risk of bleeding and death. Finally, the fact that the 
algorithm still includes HVPG measurements in part of the patients also constitutes 
a limitation given the cost and invasive nature of the technique. However, non-
invasive methods are evolving and may in the future substitute invasive HVPG 
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In summary, we have demonstrated in a large series of patients with cirrhosis 
presenting with a recent episode of variceal bleeding that the absence of ascites/HE 
and the finding of a baseline HVPG ≤16mmHg represent additional criteria of good 
outcome during subsequent treatment with the standard of care (NSBBs plus EBL). 
Restricting measurement of the HVPG response to patients presenting with ascites 
and/or HE at the time of bleeding who have a basal HVPG >16mmHg significantly 
decreases the “grey” zone, and reduces by 42% the number of HVPG measurements 
required for risk stratification. Therefore, the new strategy has advantages over the 
previously defined criteria for a good hemodynamic response to beta-blockers and 
may facilitate adopting therapeutic decisions based on expected outcomes and risk 
stratification. 
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FIGURE LEGENDS
Figure 1: Classic algorithm of HVPG-response (A) to stratify the rebleeding risk at 4 years (B) 
and rebleeding/OLT free survival (C).
Figure 2: New algorithm including: ascites and/or HE, basal HVPG of 16mmHg, HVPG-response 
(A) to stratify the rebleeding risk at 4 years (B) and rebleeding/OLT free survival (C).
Figure 3. Number of HVPG measurement required for risk stratification using the old algorithm 
(left) and the new algorithm (right).
Figure 4: Validation set (n=231 patients who received NSBBs for rebleeding prophylaxis): The 
prognostic performance of the proposed stepwise algorithm considering at high risk patients with 
ascites and/or HE, basal HVPG>16mmHg who were non-responders to NSBBs was excellent.
Supplementary Figure 1: Among patients with ascites and/or HE protective factors for 
rebleeding (A) and rebleeding/OLT free survival (B) were: having basal HVPG ≤16mmHg or 























Bleeding + ascites 
and/or HE 
p* 
Number of patients 193 73 79 41 --- 120 --- 
Age (years) 58(12) 56 (12) 60 (10) 57 (13) 0.447 59 (11) 0.081 
Sex (% of male)  75 74 73 78 0.680 75 0.866 
Alcohol Etiology (% of patients) 60 52 65 66 0.108 65 0.095 
Active alcoholism (% of patients) 50 45 50 56 0.264 52 0.375 
MELD score  13.2(4.3) 11.4 (2.5) 13.2 (4.0) 16.7 (5.2) <0.001 14.4 (4.7) <0.001 
Ascites (% of patients) 60 0 94 100 <0.001 96 <0.001 
Hepatic encephalopathy (% of patients) 24 0 6 100 <0.001 38 <0.001 
Albumin (g/L) 28.4(5.4) 30.5 (4.9) 28.9(4.6) 23.3(4.5) <0.001 27.0 (5.2) <0.001 
Bilirubin (mg/dL) 2.5(2.7) 1.9 (1.2) 2.3(1.8) 4.2(4.9) <0.001 2.9 (3.3) 0.007 
Creatinine (mg/dL) 1.00(0.74) 0.83 (0.20) 1.05(0.75) 1.21(1.17) 0.008 1.11 (0.92) 0.002 
Hematocrit (%) 27.8(5.4) 29.8 (4.5) 27.2(5.6) 25.3(5.3) <0.001 26.6 (5.5) <0.001 
Sodium (mEq/L) 137(4) 137 (4) 136(5) 137(6) 0.475 136 (5) 0.154 
Platelets (103/mm3) 96.9(49.0) 89.7 (46.5) 101.4(45.8) 101.3(57.9) 0.166 101.4 (50.1) 0.109 
Prothrombin Activity (%) 62(14) 68.1 (13.0) 62.1(13.6) 54.7(11.7) <0.001 59.5 (13.4) <0.001 
Small/large varices (% of patients) 6/94 10/90 4/96 5/95 0.225 4/96 0.136 
% of patients who stopped NSBBs 7 6 9 5 0.944 8 0.773 
Basal HVPG (mmHg) 20.8(4.7) 19.6 (4.9) 21.4(4.4) 22.0(4.8) 0.007 21.6 (4.5) 0.006 
Patients with basal HVPG≤16mmHg (%) 18 25 14 12 0.064 13 0.053 
HVPG decrease (%) during NSBBs  12.6(17.2) 14.4 (19.1) 13.1(15.6) 8.2(16.5) 0.084 11.5 (16.0) 0.254 
HVPG-responders (%) 37 47 37 20 0.005 31 0.032 
*p value <0.05 means significant difference between the cohort presented with bleeding as only decompensation event vs bleeding on top of  ascites 




Table 2: Multivariate analysis for rebleeding and rebleeding/OLT-free survival. The Hazard Ratios (HRs) for the condition of “high-risk” proposed 
by the new algorithm were adjusted for all variables differently distributed in high-risk vs low-risk patients and associated with the event at the 
univariate analysis with a p<0.1 for each clinical end-point (see supplementary Tables 1-2). 
 
REBLEEDING  
competing risk analysis-FineGray model 
SURVIVAL 
Free of rebleeding/OLT 
Cox proportional hazard model 
INDEPENDENT VARIABLES  HR 95%CI p HR 95%CI p 
Age (per year of increase) NA NA NA 0.999 0.979-1.020 0.937 
MELD score (per one unit of increase) 1.000 0.934-1.071 1.000 1.042 0.993-1.095 0.097 
Hematocrit (per % of increase) 0.984 0.926-1.045 0.623 0.989 0.942-1.038 0.657 
Albumin (per g/L of increase) 0.997 0.935-1.063 0.593 1.003 0.957-1.052 0.886 
Sodium (per mEq/L of increase) NA NA NA 0.943 0.899-0.990 0.018 
High-risk (ascites/HE, HVPG>16mmHg 
and HVPG non-responders) 
2.739 1.436-5.226 0.002 2.539 1.546-4.169 <0.001 
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Number of HVPG measurement required for risk stratification
Old algorithm New algorithm
193 patients 193 patients
193 baseline HVPG
193 second HVPG for hemodynamic response
386 HVPG measurements 224 HVPG measurements
(-42% Vs Old algorithm)
104 patients with ascites and HVPG >16mmHg (54%)
16 patients with HVPG≤16mmHg (8%)
120 patients with ascites
73 patients w/o ascites (38%)
Algorithm based on HVPG response in all patients Algorithm based on HVPG response only in patients
with ascites and/or HE and basal HVPG >16mmHg
all requiring measurement of HVPG response
not needing HVPG measurement
needing at least one HVPG measurement
needing only one HVPG measurement
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